Showing results (131-140 of 451) with videos related to
Sort By:
Pageof 46
Tumori|June 30, 1979
Alien H-2 antigens on a chemically induced fibrosarcoma: further evidence in crude membrane and soluble extracts of the tumorM A Pierotti, S Miotti, G Invernizzi, et al.International Journal of Cancer|December 15, 1988
Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burdenF Formelli, C Rossi, M L Sensi, et al.FEBS Letters|November 29, 1993
Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNAC Melani, A Silvani, G Parmiani, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1989
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cellsM Radrizzani, C Gambacorti-Passerini, G Parmiani, et al.Rivista Dell'Infermiere|January 1, 1997
[Professional and working conditions of newly licensed nurses in the province of Trento]C Castelli, L SaianiAssistenza Infermieristica E Ricerca : AIR|July 26, 2000
[Characteristics of nursing students attending the University Courses for Nursing Diploma at Trento: reasons for their choices in the first trimester]C Castelli, L SaianiCancer Immunology, Immunotherapy : CII|January 1, 1988
Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytesD Taramelli, A Mazzocchi, C Clemente, et al.Immunobiology|August 1, 1983
Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cellsM P Colombo, M A Pierotti, D Ballinari, et al.British Journal of Cancer|July 1, 1986
Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumventionR Supino, E Prosperi, F Formelli, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1997
TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patientsC Maccalli, C Farina, M Sensi, et al.Pageof 46